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 CURRENTOPINION Exercise medicine for advanced prostate cancer
Nicolas H. Hart, Daniel A. Galva˜o, and Robert U. Newton
Purpose of review
Exercise is a provocative medicine, known for its preventive, complimentary and rehabilitative role in the
management of cancer. Impressively, exercise is also emerging as a synergistic and targeted medicine to
enhance symptom control, modulate tumour biology and delay disease progression, with the potential to
increase overall survival. Given the complex clinical presentation of advanced prostate cancer patients and
their omnipresent comorbidities, this review describes the current and potential role of exercise medicine in
advanced prostate cancer.
Recent findings
Exercise has been shown to be safe, feasible and effective for advanced prostate cancer patients, inclusive of
patients with bone metastases; a previously excluded population due to patient and clinician fear of adverse
events. Preclinical data provide insight into the ability of exercise to modulate cancer-specific outcomes, may
synergistically increase the potency of chemotherapy and radiotherapy and may endogenously and/or
mechanically suppress tumour formation, growth and invasion in visceral and skeletal tissue. Epidemiological
studies have also shown an association between physical activity and increased survival.
Summary
Exercise oncology is rapidly evolving, with impressive possibilities that may directly improve patient
outcomes in advanced prostate cancer. Research must focus on translating preclinical trials into human
clinical trials and investigate the direct effect of exercise on overall survival.
Keywords
adjuvant, autoregulation, synergistic, targeted, tumour biology
INTRODUCTION
Prostate cancer represents the secondmost common
cancer in men worldwide, and is predicted to
substantially rise in developed nations owing to
sustained population growth, increased life expect-
ancies and an ageing population [1,2]. Fortunately,
the advent and widespread adoption of serological
prostate-specific antigen (PSA) screening pro-
grammes has notably improved the early detection,
diagnosis, treatment and management of prostate
cancer, demonstrably improving survival outcomes.
Impressively, this has led to an increase in 5-year
survival rates from68 to99.7% in recent decades,
with a 10 and 15-year survival rate of 99 and
94%, respectively, when detected early [3,4]. As
such, prostate cancer survivorship is an emerging
and critically important field of study, focused on
the effective management of new, recurrent and
persistent symptoms across the disease spectrum
to explicitly enhance patient health, wellbeing
and quality of life [5,6]. Unfortunately, most studies
exploring survivorship focus their attention on the
initial years of posttreatment survival, with limited
attention given to patient needs later in the disease
trajectory [6,7
&
] when recurrence, castrate resistance
and/or metastatic proliferation inevitably result in
progression to advanced prostate cancer, whereby
patient needs magnify [7
&
].
Advanced prostate cancer is characterized by the
recurrence and/or invasion of the primary carci-
noma to secondary sites (i.e. nodal, visceral or
skeletal metastases) and/or the development of
resistance to first-line hormone therapy (androgen
deprivation therapy; ADT) whereby androgen inde-
pendent progression occurs (castrate-resistant pros-
tate cancer; CRPC) [8]. Men with advanced prostate
cancer present a significant challenge to clinicians,
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because of their high disease burden and omnipre-
sent comorbidities, in addition to common treat-
ment-related side-effects stemming from second-
line hormone therapies (abiraterone and enzaluta-
mide) [9], first-line and second-line chemotherapies
(docetaxel and cabazitaxel) [10], radionuclear thera-
pies (strontium-89, samarium-153 and radium-223)
[11] and emergent immunotherapies [12], the
optimal sequencing of which has yet to be deter-
mined. Indeed, the vast majority of advanced pros-
tate cancer patients (>80%) will develop bone
metastases, which is a currently incurable stage of
disease leading to palliation, poor prognoses and
numerous clinical complications [13,14
&
]. It is there-
fore a high priority and of significant clinical inter-
est to devise and implement strategies to safely and
effectively reduce the disease burden and treatment
toxicity profile of advanced prostate cancer patients;
particularly, strategies which are inexpensive, non-
invasive and able to be widely implemented.
Exercise is an emerging and provocative therapy
in oncology, inherently aligned with the ‘exercise
medicine’ movement [15–17], which shows excel-
lent promise to meet this patient need.
EXERCISE MEDICINE
Exercise was first considered a potential therapy for
cancer patients and survivors in the mid-1980s [18–
20], with only a further 25 exercise oncology stud-
ies reported in the subsequent two decades [21].
Increasingly, over the last decade, exercise medicine
has rapidly ascended as a key field of interest in the
prevention [22] and management [23] of cancer,
while emerging as a potential therapeutic agent to
delay disease progression [24
&&
–26
&&
,27,28
&
,29] and
increase overall survival [29,30,31
&&
,32
&&
,33,34].
Primarily, researchers have focused their attention
on the use of exercise in the neoadjuvant and adju-
vant settings as a preventive, preparatory and reha-
bilitative tool for surgery (presurgical and
postsurgical programmes) [35,36], and for symptom
control during and/or following primary treat-
ments, including radiotherapy, chemotherapy and
hormone therapy (particularly ADT) postdiagnosis
[37–40]. Collectively, this body of research has pro-
duced level 1 evidence [23], asserting the role of
exercise for cancer patients to improve quality of life
across several key metrics, including the mitigation
of cancer-related fatigue [41
&
] and restoration of
physical function and exercise capacity [22,42],
notably in response to treatment driven changes
in body composition [23]. The effectiveness of exer-
cise as a neoadjuvant and adjuvant therapy to min-
imize, manage and, in some cases, reverse the side-
effects of primary therapies has been promising to
date [42–46].
Exercise oncology (i.e. the application of exer-
cise medicine in cancer) has also continued to
broaden, with several novel avenues being explored
through preclinical orthotopicmodels that have the
potential to significantly improve outcomes in
advanced prostate cancer patients once translated
to human clinical trials [47,48,49
&&
,50
&&
,51–54].
Indeed, the impressive ability of exercise to poten-
tially modulate cancer-specific outcomes is of direct
clinical interest and warrants rigorous scientific
inquiry. Beyond neoadjuvant and adjuvant appli-
cations, exercise is emerging as a synergistic medi-
cine (i.e. increasing the potency or effectiveness of
concomitantly applied therapies) and targeted
medicine (i.e. exerting its own systemic and local-
ized anticancer effects, independent of other thera-
pies) to underpin delays in disease progression and
improvements in survival for advanced cancer
patients. For example, synergies between exercise
KEY POINTS
 Exercise is a safe and effective medicine for advanced
prostate cancer, including for patients with bone
metastases; a historically excluded patient population
with a high disease burden and magnified clinical
needs. Advanced prostate cancer patients should
therefore participate in exercise programmes, under
clinical supervision.
 Exercise may act synergistically to improve the potency,
delivery, effectiveness and tolerance of chemotherapy
and radiotherapy in advanced prostate cancer patients.
This has been presented in preclinical orthotopic
models to date. Future studies should aim to translate
findings to patient-focused human clinical trials.
 Exercise may endogenously and mechanically suppress
tumour formation, growth and invasion in visceral and
skeletal tissue by modulating cancer-specific outcomes.
This has been demonstrated in preclinical orthotopic
models to date. Future studies should aim to translate
findings to patient-focused human clinical trials.
 Physical activity has been associated with lower risk of
cancer-specific and all-cause mortality. However,
exercise will likely yield even greater survival benefits,
and this is being investigated by the INTERVAL-MCRPC
clinical trial, using metastatic castrate-resistant prostate
cancer patients, launched in 2016.
 Exercise programmes designed for advanced prostate
cancer patients should always be supervised,
individualized, periodized, progressive and
autoregulated. Autoregulation is a particularly
important for this patient population, given their disease
profile, age, omnipresent comorbidities and associated
treatment toxicities over time.
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and chemotherapy have been identified
[49
&&
,50
&&
,51], with aerobic exercise demonstrating
an ability to interfere with tumour-driven dysregu-
lation of angiogenesis; acting to restore and normal-
ize tumour vasculature, thus improving blood
supply and tumoral perfusion as mechanisms to
enhance chemotherapeutic efficacy [49
&&
,50
&&
,
51–55]. This same angiogenic response may also
synergistically improve the effectiveness of radio-
therapy [51–55], as reversible DNA damage can be
stabilized if sufficient oxygen is present (i.e. oxygen
enhancing effect of radiotherapy) [55], which could
be optimized through exercise driven provascula-
ture changes, resulting in increased tumour cell
death. This is yet another avenue of exploration
for future research. When extrapolated, this may
also lead to synergistic improvements in the
potency of other systemically delivered therapies
inclusive of emerging immunotherapies in the pros-
tate cancer treatment mix, or endogenous immune
agents produced by various organs in the body that
are driven by exercise [15].
Provocative evidence also exists to promote the
potential independent role of exercise medicine for
advanced prostate cancer patients. Putatively, exer-
cise is thought to alter tumour biology by numerous
mechanisms in response to a variety of modes and
dosages (Fig. 1) [24
&&
]; however, the direct influence
of exercise on tumour biology remains largely
unknown, despite many hypothesized mechanical
and nonmechanical mechanisms of action
[47,48,49
&&
,50
&&
,51–59,60
&
]. Specifically, exercise
regulates endocrine–paracrine activity, immune
system function, blood glucose and cholesterol
levels, insulin responses and body composition
and may epigenetically modulate tumour cell
FIGURE 1. Potential mechanisms by which exercise might modulate tumour biology and delay disease progression. Thus far,
the exact mechanisms of this effect have yet to be established; although, some evidence exists for a contribution from a variety
of diverse mechanisms. Reprinted with permission [24&&].
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proliferation, telomere length, telomere enzyme
activity, tumour vascularity, oxidative stress
capacity, platelet cloaking and platelet adhesion
[61–66]. This emerging field of exercise medicine
(i.e. biological alterations driven from biomechan-
ical stimuli) [67] in exercise oncology presents prac-
titioners with unique opportunities to target
tumour formation, growth and invasion of primary
or secondary prostate carcinomas through exercise
interventions. For example, aerobic exercise has
been shown to stimulate natural killer cell pro-
duction, mobilization and infiltration in to
tumours, producing an approximate 60% reduction
in tumour incidence and growth across several
different preclinical tumour models [68
&&
]. Sim-
ilarly, controlled mechanical compressions of
skeletal sites with known bonemetastases have been
shown to interfere with tumour-driven dysregula-
tion of osteogenesis, producing an approximate
80% reduction in tumour growth rate in osteolytic
models, while preserving skeletal integrity by
approximately 70% in loaded versus unloaded con-
ditions [47]. Cautiously, these preclinical findings
use animal models over disparate time-periods, and
require confirmatory human trials, some of which
are currently in progress [69
&
], though provide
promising insights into exercise medicine inde-
pendent of other therapies.
Epidemiological studies support the role of
physical activity (i.e. incidental and/or nonspecific
activities requiring bodily movement) and its associ-
ation with delayed disease progression and increased
overall survival [27,28
&
,29,30,31
&&
,32
&&
,33,34].
Specifically, prediagnosis physical activity has been
linked to tumour vessel normalization, which
reduces the propensity of tumours to metastasize
(i.e. delay disease progression) and has the potential
to produce a 6.6–17.1-fold risk reduction in prostate
cancer mortality [70
&&
,71]; whereby postdiagnosis
moderate-to-vigorous physical activity has been
linked to reductions in all-cause and prostate can-
cer-specificmortality of between 30 and 60% (pooled
risk reduction¼0.62, 95%confidence interval: 0.47–
0.82) [31
&&
,32
&&
,33,34,72
&
], depending on the type,
duration and frequency of physical activity reported.
However, these studies provide associations using
patient self-reported measures only and do not dem-
onstrate a dose–response or load–adaptation insight
into cause and effect between physical activity, dis-
ease progression or overall survival. Consequently,
studies are yet to explore the role of exercise (i.e.
purposeful, prescriptive, programmed and progress-
ive activities of a specific nature; thenomenclature of
which is often incorrectly used synonymously with
physical activity) on disease-specific endpoints and
such interventions would most certainly produce
even greater benefits than those analysing self-
reported physical activity. To address this need, a
Global Action Plan (GAP4) has been funded by the
Movember Foundation, with a multinational Phase
III exercise trial (INTERVAL-MCRPC: https://clinical-
trials.gov/ct2/show/NCT02730338) launched, and
currently underway to directly examine the effects
of exercisemedicine ondisease progression and over-
all survival in metastatic castrate-resistant prostate
cancer patients [73
&
].
TREATMENTS, TOXICITIES AND EXERCISE
Exercise and antiandrogen therapies
Endocrine modification therapies are common first-
line treatments for prostate cancer (beyond radical
prostatectomyand radiation therapy), aiming to sup-
press testosterone released from the testes and/or to
block androgen receptor uptake of testosterone by
cancer cells, producing an environment commensu-
ratewithcastration [74,75]. ADTremains theprimary
hormonal therapy for local and metastatic prostate
cancer patients, proving an extremely successful
pharmacological avenue to slow the progression of
certain prostate cancers. On the contrary, long-term
exposure to ADT inevitably leads to resistance, thus
becoming ineffective due to tumour adaptability,
desensitization to drug action and systemic acclimat-
ization to the castrate environment [74–77]. This
generates a rapid rise in PSA levels and velocity,
indicating an advancement of the disease to CRPC.
Consequently, extragonadal androgen sources start
to sustain tumour growth despite castrate levels of
testosterone, requiring second-line therapies to be
introduced into the treatment mix [76,77].
Novel pharmacological agents which inhibit
androgen receptors have recently been developed
as second-line hormonal therapies to countenance
extragonadal sources of androgen, including deri-
vations from blood and bone marrow, successfully
extending overall survival by 4–5 months [78,79]
in castrate-resistant patients. Specifically, Abirater-
one Acetate (Zytiga; Janssen, Beerse, Belgium) and
Enzalutamide (Xandti; Astellas, Illinois, USA) are
prominent antiandrogen drugs in the standard of
care landscape when treating CRPC patients, which
act as selective inhibitors to obstruct androgen
uptake and utilization by prostate carcinomas
regardless of production site (gonadal or extragona-
dal), thus considered to be very effective at suppress-
ing testosterone in the testes, adrenal glands and the
tumour itself, reducing testosterone levels by a fur-
ther 90% beyond castrate levels [74–80]. Although
androgen-deprivation therapies are proving effec-
tive in slowing prostate cancer progression, with
Renal and urological problems
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improvements to survival; observational and longi-
tudinal evidence highlight the burden of treatment
to patients, which may be exacerbated by novel
antiandrogen therapies [81,82
&
] (Fig. 2), yet could
potentially be managed through exercise.
ADT induces rapid loss ofmuscle and bonemass,
increased central adiposity and body fat, and is
therefore a precursor for the onset of metabolic
diseases and other comorbidities such as type II
diabetes and/or cardiovascular disease; culminating
in physical and functional decline, increased
fatigue, heightened fragility, decreased psychosocial
health and a reduced quality of life [37–40,41
&
,
42–46,82
&
,83–86]. Given that novel antiandrogen
therapies induce an even greater blockade of andro-
gen beyond castration levels (i.e. maximal androgen
suppression), these reported side-effects are likely to
be more pronounced (Fig. 3), presenting even
greater clinical concerns for advanced prostate can-
cer patients. Although exercise is demonstrably
Inhibited
Muscle Growth
Inhibited
Muscle Repair
Increased 
Muscle Atrophy
Motor Unit 
Recruitment
Muscle Fiber
Innervation
Release of
Acetylcholine IGF-1 / IGF-1R
Β -catenin
PI3K/Akt/mTOR
UP Pathway
Apoptosis
Autophagy
Decreased
Muscle Function
HGF
Satellite Cells
Androgen Receptor
Further inhibited by Abiraterone and Enzalutamide
Note: PI3K = Phosphoinositide 3-kinase; Akt = protein kinase B; mTOR = mammalian Target Of Rapamycin; IGF-1 = Insulin-like 
Growth Factor 1; IGF-1R = Insulin-like Growth Factor 1 Receptor; HGF = Hepatocyte Growth Factor; UP = Ubiquitin Proteasome.
FIGURE 2. Skeletal muscle depletion (sarcopenia-related disorders) induced by androgen deprivation therapy, expected to be
greater in severity for castrate-resistant prostate cancer patients treated with antiandrogen therapies generating maximal
androgen suppression. Adapted with permission [82&].
FIGURE 3. Theoretical model illustrating musculoskeletal fitness reduction during normal aging, androgen deprivation therapy
and maximal androgen suppression, highlighting the potential role of exercise to increase musculoskeletal fitness and improve
physical reserve capacity. Adapted with permission [46].
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beneficial for patients receiving ADT to prevent,
preserve or reverse treatment-related side-effects
[45,46], this has yet to be demonstrated in patients
receiving maximal antiandrogen suppression.
Indeed, exercise is very likely to mitigate fatigue
commonly reported by patients on novel antiandro-
gen therapies [41
&
,81], andmay synergistically assist
in themitigation of resistance to enzalutamide, with
natural killer cells recently implicated in the sup-
pression of androgen receptor splicing variant 7
(ARv7) (i.e. an androgen receptor splicing variant
linked to the development of resistance) [87
&&
]. As
natural killer cell production and mobilization
increases following exercise [68
&&
], by extension,
this may aid in the suppression of ARv7; however,
further research is required.
Exercise and chemotherapy
Chemotherapies provided to patients with
advanced prostate cancer aim to provide symptom
control, delay disease progression and increase sur-
vival; however, often present with their own clinical
challenges and side-effects. Docetaxel remains the
mainstay of first-line taxanes, with cabazitaxel
established as a second-line taxane in eligible
patients (i.e. consideration of bonemarrow reserves,
bone marrow quality, hepatic function and patient
presentation) in favour of mitoxantrone; with cab-
azitaxel also available as a first-line taxane for
patients resistant to docetaxel [10,74]. Owing to
the side-effects of cytotoxic therapies, coupled with
side-effects of other therapies (i.e. ADT in hormone-
sensitive patients), patients may not tolerate full
dosages across all cycles of treatment, and in some
cases may be ineligible for further chemotherapy
treatments if bone marrow and organ function is
compromised [88–90]. Further, patients commonly
present with high levels of fatigue, physical impair-
ment and develop neutropenia following chemo-
therapy [91–94] whichmay lead to patients electing
to refuse further chemotherapy dosages or undergo
additional courses. Strategies to alleviate treatment
toxicities and maintain hepatic and physical func-
tion are thus required.
Exercise is well established as a therapy to miti-
gate cancer-related fatigue [22,41
&
], restore physical
function and enhance physical fitness [23,42,44,95];
however, exercise may have broader clinical benefits
for prostate cancer patients receiving chemotherapy.
For example, neoadjuvant exercise may improve
patient preparation and physical tolerance of first-
line chemotherapy, inclusive of posttherapy recov-
ery, with body composition established as a predictor
of chemotherapeutic toxicity [96
&&
]. Furthermore,
adjuvant exercise may synergistically increase cyto-
toxic circulation and intratumoural delivery of che-
motherapy, thus increasing therapeutic potency
[49
&&
,50
&&
], and may mitigate, restore or reverse si-
de-effects associatedwith chemotherapy, inclusiveof
reductions in neutropenia onset, duration and
severity of nadir (Fig. 4) following proposed improve-
ments in immune function [97–99]. Neoadjuvant
and adjuvant exercise therefore has the potential
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FIGURE 4. Theoretical model illustrating the potential acute and aggregate neutrophil response to exercise (dashed line)
versus usual care (solid line) during chemotherapy cycles, highlighting a potentially reduced severity and duration of nadir
(i.e. region of lowest neutrophils during neutropenia, where infection risk is at its highest).
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to assist patients to receive their full individual and
aggregate doses of chemotherapy, and coupled with
posttherapy exercise, may promote bone marrow
quality [97] and improve patient physical condition
to heighten clinical eligibility to receive and tolerate
second-line chemotherapy; two clinically meaning-
ful outcomes for advanced prostate cancer patients
that are worthy of exploration.
EXERCISE PROGRAMMING
Clinical considerations
Owing to their variable treatment histories, lifestyle-
related and disease-related comorbidities and age-
related decline, advanced prostate cancer patients
will present with complex clinical cases that will
influence the modality, volume, frequency,
duration and intensity of exercise prescribed, and
the manner in which their exercise programme
progresses. Commonly amongst them is bone meta-
stases, a historical barrier to exercise observed in
over 80% of advanced cancer patients [100,101].
For patients with bone metastases, it is currently
recommended to use exercises that avoid directly
loading skeletal regions where metastatic lesions
exist (Table 1) [102]. Current studies exploring the
safety, feasibility and preliminary efficacy of tar-
geted loading of skeletal sites with bone metastases
are currently underway [69
&
], with results soon to
be released.
Autoregulation, periodization and exercise
selection
Advanced prostate cancer patients may present with
numerous treatment side-effects of varying magni-
tudes at a given exercise session, or across multiple
exercise sessions. To accommodate for transient
changes and fluctuations in a patient’s wellbeing
through-out courses of treatment and through-out
their disease progression, all exercise programmes
should be individualized (i.e. based on a needs
analysis and physical assessment) and progressive
using autoregulation (i.e. a method in which cancer
patients progress at their own pace based on daily
and weekly variations in their health, performance
capability, recovery capacity or scheduling commit-
ments) [103,104]. Autoregulation is an important
concept, allowing patients to consultatively self-
determine their capabilities at each session collab-
oratively with the supervising clinical exercise
physiologist, thereby lowering intensity or volume
if the patient is fatigued or unwell, or raising inten-
sity or volume if the patient is energetic and motiv-
ated. Commensurate with other standard exercise
principles, exercise programmes should be perio-
dized (i.e. the systematic planning and phasic organ-
ization of exercise volume and intensity, including
deloading periods to promote patient recovery),
commence conservatively, and include a variety
of exercise types and modalities.
Advanced cancer patients should receive medical
clearances from either their oncologist (i.e. cancer-
specific medications and clearances), cardiologist
(i.e. cardiac-specific medication and clearances) and/
or general practitioner (i.e. other medications and
comorbidity clearances) prior to engaging in an
exercise programme, which may limit the modality
of exercise permitted. Nevertheless, exercise pro-
grammes should ideally involve a multimodal
approach with aerobic and resistance exercise of vary-
ing intensities and volumes to target the cardiorespir-
atory andmusculoskeletal systems, respectively (Table
2), and to promote various biochemical, hormonal
(endocrine–paracrine) and immune responses to dis-
parate modalities. Current clinical exercise guidelines
[105–107] recommend achieving a combination of
150min of moderate, or 75min of vigorous aerobic
exercise coupled with 2–3 resistance exercise sessions
Table 1. Modular multimodal exercise programme for patients with bone metastases
Resistance Aerobic Flexibility
Metastases site Upper Trunk Lower WB NWB Static
Pelvis H H H H H
Lumbar spine H H H H
Thoracic spine/ribs H H H H H
Proximal femur H H H H H
All regions H H H H
H, target exercise region; , exclusion of shoulder flexion/extension/abduction/adduction – inclusion of elbow flexion/extension; , exclusion of hip extension/
flexion – inclusion of knee extension/flexion; , exclusion of spine/flexion/extension/rotation; NWB, nonweight bearing (e.g. cycling); WB, weight bearing
(e.g. walking). Reproduced from [102].
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for cancer patients and survivors. However, owing to
heightened clinical concerns and patient fear of
skeletal and other adverse events [69
&
], only 30%
of advanced prostate cancer patients with bonemeta-
stases reported meeting aerobic exercise guidelines;
with the remaining 70% either insufficiently or
completely inactive (i.e. performing no aerobic exer-
cise at all) [14
&
]. Given the historical safety concerns
surrounding resistance exercise in this population
(with safety and feasibility recently demonstrated
[100,101]), resistance exercise participation would
be even lower than those reported for aerobic exercise.
Although any activity is better than no activity, it is
incumbent upon clinicians to promote patient
engagementwithexercisephysiologistsandtreatexer-
cise as a medicine for advanced prostate cancer, one
which all patients should participate.
CONCLUSION
Exercisemedicine is rapidly evolving as an emerging
and provocative therapy in oncology, with excellent
promise to meet the broad and magnified needs of
advanced prostate cancer patients. This review high-
lights established clinical evidence, developing pre-
clinical evidence and potential future avenues of
novel research pertaining to the role of exercise as
an adjuvant, synergistic and targeted therapy. In
Table 2. Exercise programming across modalities: definitions and recommendations
Exercise modality Description and recommendation
Aerobic exercise Exercise that provides stress to the cardiorespiratory system (heart, blood vessels and lungs), and targets
cardiometabolic health. This can be performed at moderate-to-high intensities, under continuous or intermittent/
interval conditions (MICT/HIIT)
Examples: cycle ergometers, treadmills, cross-trainer ergometers
MICT (moderate
intensity continuous
training)
Constant moderate intensity work at a level that can be maintained for an extended period of time without fatigue.
Patients may require MICT sessions to be split into discrete bouts at the earlier stages of their programme, until
fitness and endurance develops
Intensity: RPE 5–6, (60–70% HRmax); RPE 4 during deload
Work durations: 20–40min
Rest durations: 0–2min
Number of sets: 1–2 sets
HIIT (high-intensity
interval training)
Short bouts of high-intensity work, separated by periods of active or passive recovery. Patients may have a transient
increased in risk of fall for 10min following the completion of a HIIT session. Monitoring patient response during
and following work bouts is required
Intensity: RPE 8–9, (80–90% HRmax); RPE 7 during deload
Work durations: 30–60 s
Rest durations: 90–120 s
Number of sets: 4–6 sets
Resistance exercise Exercise that is performed against resistance (bodyweight or external load) and aims to stress the musculoskeletal
system (muscle-bone), with muscle a key secretory and endocrine organ. Dynamic, compound, whole-body
movements should be performed first, prior to isolated single-joint activities. Trunk flexion and extension exercises can
be incorporated into the cool-down portion of the programme, along with flexibility exercises for the exercised muscle
Examples: weight machines, free weights (dumbbells and barbells), body-weight exercises, weighted objects (gym
sticks and power bags)
Intensity: 6–12 RM
Number of sets: 2–4 sets
Number of Exercises: 6–8 involving large muscle groups
Impact exercise Exercise that involves impact, putatively thought to target the skeletal system and bone health. Patients with bone
metastases are currently contraindicated for impact exercise, as safety has yet to be demonstrated in these
patients. Patients with no known bone metastases can perform impact exercises as tolerated. Start conservatively,
from a foundation of 12–36 resistance exercise sessions, and build into programme for volume and difficulty
Examples: marching, two-legged jumps, hopping, skipping, bounding
Repetitions: 10–15 repetitions
Number of sets: 2–3 sets
Number of exercises: 2–4 exercises involving upper and lower body
HIIT, high-intensity interval training; HRmax, heart rate maximum; MICT, moderate-intensity continuous training; RM, repetition maximum; RPE, rating of perceived
exertion using the BORG10 scale.
Renal and urological problems
254 www.supportiveandpalliativecare.com Volume 11  Number 3  September 2017
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
particular, we highlight the powerful potential of
exercise to enhance chemotherapeutic and radio-
therapeutic effectiveness, interfere with tumour-
driven dysregulation of angiogenesis and osteogen-
esis and delay disease progression and extend sur-
vival. Importantly, due to the complex clinical
presentations of advanced prostate cancer patients,
this review provides exercise prescription and pro-
gramming recommendations to ensure that exercise
participation is flexible and effective, yet safe and
well tolerated by patients. Lastly, we assert the need
for future research to focus on translating impressive
preclinical outcomes, to patient-focused human
clinical trials, to continue to establish exercise as
an essential therapy for inclusion into standard of
care practices in oncology.
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